Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.